The University of Chicago Booth School of Business

Harvard University

Bryn Mawr College

Dartmouth College

The Lawrenceville School

Healthcare Marketing and Strategy

•	Recruited to lead the foreign invest agenda for life sciences driving investment from the US into Sweden with focus on high-value investment, partnership, and co-development activities in personalized medicine and health technology.
o	Lead a lean global team with a mission of generating and executing deal flow between the US and Sweden.
o	Developed multiple high value deals between US investors (VC, PE, corp dev) and Swedish life sciences companies and ecosystems resulting in $2B + value creation.

Business Sweden

Director, Invest Advisory - Life Sciences, Healthcare

Multiple Progressive Roles in this Timeframe

•	Promoted to Invest In Finland US Lead with focus on high-value investment, partnership, and co-development activities in personalized medicine and healthcare technology.

US Lead, Team Finland Commercial Strategy (US Management Team Member)	                         
•	Promoted to strategic planning lead across all industry sectors supporting 13.7 B Euro in bilateral trade with the US reporting to Finland’s Ambassador to the US.
•	Lead development of Team Finland USA Annual Plan managing 20+ cross-functional team members. 
•	Nominee for Employee of the Year.

Business Finland

US Lead, Invest In Finland, Precision Medicine and Healthcare Technology

Results-oriented clinical diagnostics commercial strategy/product launch leader with deep experience in oncology, liquid biopsy, and companion diagnostics.

Services include: strategic planning, growth strategy development, sales targeting, market assessment, new product planning, business development, due diligence for product licensing and acquisitions, forecasting, commercialization strategy.

Independent

Healthcare Marketing and Strategy Consulting

Recruited to lead US market M&A and licensing search and evaluation activity for oncology, rare disease, and CNS therapeutic areas.
•	Led oncology, rare disease, and CNS therapeutic area matrix working groups including commercial, medical, and corporate strategy leadership on defining BD&L strategy and assessing target opportunities. 
o	Result: drove prioritization of acquisition pipeline within defined therapeutic areas.
•	Presented acquisition target opportunities to Bayer Pharma US president and Bayer AG senior leadership toward objective of growing top-line revenue by 2x by 2020. 
o	Developed valuation analyses and strategic assessments leading to crisp assessments of deal merits. 
o	Result: progressed subset of possible $1B+ acquisition targets to advanced stage gate of increased diligence.

Bayer Pharmaceuticals

US Business Development and Licensing (Oncology, Neurology, Rare Disease)

Multiple Progressive Roles Within Commercial Strategy/ Product Management/ Business Development
                                    
Promoted to business lead / P&L owner of portfolio of screening/detection, hereditary cancer, companion diagnostic testing products ($multi-hundred million P&L). Led all commercial strategic and tactical marketing, specialty sales ops, in-line, pipeline, in-licensing, and development efforts for a 10+ person cross-functional team.

Commercial Leadership
•	Developed, sold to senior management, and led execution of strategic and operating plans.
•	Drove organic growth of product portfolio through focused efforts of 100+ person specialty salesforce. 
o	Result: triple-digit % YOY revenue growth for newly launched hereditary cancer products.

Business Development and M&A Leadership 
•	Led commercial business development efforts for cancer and prenatal genetics test portfolios, including in-licensing and R&D pipelines. Developed tech assessments, business cases, opportunity sizing,revenue projections.
•	Developed and presented business case to Quest CEO for acquisition of critical IP.
o	Result: $740M Quest acquisition of Athena Diagnostics from Thermo Fisher.

Product Market Launch Highlights
•	Led launch of companion/complementary PDL1 diagnostic tests for breakthrough lung cancer (NSCLC) immunotherapies: Keytruda (Merck), Opdivo (BMS). 
o	Result: flawless national launch establishing Quest as pharma lab partner of choice.
•	Led product development and market launch of BRCAvantage Plus test for hereditary breast cancer risk.
o	Result: triple-digit % YOY revenue growth.
•	Led market launch of blood test for Lynch syndrome (hereditary colorectal cancer risk).
o	Result: received leadership award for exceptional market launch. 
•	Led market launch of ColoVantage, first US product for detection of colorectal cancer from a simple blood draw (liquid biopsy). (Partnership with Epigenomics).

Paul Majewski